FOR IMMEDIATE RELEASE

Distinguished Chemist Selected to Lead the Tri-Institutional Therapeutics Discovery Institute

Peter T. Meinke will take the Tri-I TDI into the next phase of growth

June 12, 2018, New York City — Peter T. Meinke, PhD, an accomplished chemist with more than 30 years of industry and academic experience, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI). A pioneering academic-industry collaboration, the Tri-I TDI is designed to expedite early-stage small molecule and antibody drug discovery into novel treatments for patients.

The Tri-I TDI is an independent, nonprofit corporation created by Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medicine, in partnership with Takeda Pharmaceutical Company Ltd. Dr. Meinke will be the Sanders Director of the Tri-I TDI and Director of its Sanders Innovation and Education Initiative, which was created in recognition of the $15 million gift from Lewis and Ali Sanders to help establish the institute in 2013. (The couple subsequently made an additional $15 million gift to the TDI in 2015.)

Since last year, Dr. Meinke has been Vice President of Preclinical Development at the Tri-I TDI, as well as the Vice President of Medicinal Chemistry at Bridge Medicines, the Tri-I TDI’s for-profit collaborator. Dr. Meinke was also recently Executive Director of Medicinal Chemistry for Merck, based in Shanghai, China. While at Merck, he contributed to the discovery and development of the Merck drug elbasvir, which treats chronic hepatitis C infection in adults. This work earned him and his colleagues the American Chemical Society's Heroes of Chemistry Award in 2017. He is also the founder and President of Meinke Pharma Consulting.

“After an exhaustive national search for a new CEO, we are confident that Dr. Meinke is the right person to accelerate our exciting next phase of the Tri-Institutional Therapeutics Discovery Institute,” said David Scheinberg, MD, PhD, a member of the Tri-I TDI’s board of directors and head of the search committee, as well as Chair of Memorial Sloan Kettering’s Molecular Pharmacology Program and Director of the Experimental Therapeutics Center.

“My time at the TDI over the past year and a half has demonstrated to me the transformational power afforded by marrying the creativity of Tri-I TDI scientists with experienced drug discovery professionals,” said Dr. Meinke. “It is a privilege for me to build on the momentum of the TDI as we continue to realize its mission of accelerating basic science discoveries into novel therapeutics.”

“Over the past five years, access to the resources of the Tri-I TDI has been transformative for our faculty members, enabling them to pursue novel therapeutics based on their fundamental discoveries,” said Richard P. Lifton, MD, PhD, President of The Rockefeller University. “Peter
has an extraordinary track record in drug development, and I have no doubt that the Tri-I TDI will continue to flourish under his leadership — to the benefit of Tri-I scientists and medicine as a whole.”

“Dr. Meinke’s depth of experience in pharmaceutical development and business acumen are invaluable assets to the Tri-I TDI and its potential to influence the drug development landscape,” said Augustine M.K. Choi, MD, the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine. “I am confident that his strategic approach will help advance our scientific discoveries and those of our collaborators to benefit patients.”

“Dr. Meinke’s sterling experience and exceptional vision and leadership will help continue the success of the Tri-I TDI and aid our mission to transform New York City into a renowned hub for biotechnology and life sciences,” said Craig Thompson, MD, President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center.

The Tri-I TDI relies on recommendations from its scientific advisory board to select research projects that hold the greatest scientific promise and present the most innovative approaches to advancing human health. Three projects from a portfolio of 57 that the Tri-I TDI supports have generated enough evidence to demonstrate that they are now ready for the next phase of therapeutic development, which is intended to lead to investigational new drug applications with the US Food and Drug Administration. As many as eight other Tri-I TDI projects could go on to further therapeutic development this year.

Dr. Meinke will oversee a staff of 30, many of them top scientists from large pharmaceutical companies who were recruited to work in a more lean and autonomous culture. While most of the funding for the Tri-I TDI comes from philanthropic support, the goal of the Tri-I TDI is to become self-sustaining.

Over the course of his career, Dr. Meinke has published more than 90 academic papers and filed nearly 40 patent applications. He has been a member of the American Chemical Society since 1983. He earned his PhD in organic chemistry at Syracuse University following undergraduate education at Eckerd College and did his postdoctoral work at Columbia University.

Dr. Meinke succeeds Michael Foley, PhD, who had led the Tri-I TDI since its inception.

###

**About Tri-I TDI**
A novel partnership of academic institutions, the Tri-Institutional Therapeutics Discovery Institute (TRI-I TDI) links researchers in basic and clinical science with experts in drug discovery from the biotechnology and pharmaceutical industries, with the goal of more efficiently translating discoveries into therapies for disease. Launched in 2013 in New York City, the TRI-I TDI focuses on the early stages of developing compounds and biologic agents, and conducts the proof-of-concept studies needed to demonstrate that drug candidates can successfully alter the course of a disease. For more information, visit [www.tritdi.org](http://www.tritdi.org).

**About Memorial Sloan Kettering**
Memorial Sloan Kettering is the world’s oldest and largest private cancer center, home to more than 17,000 physicians, scientists, nurses, and staff united by a relentless dedication to
conquering cancer. As an independent institution, MSK combines 130 years of research and clinical leadership with the freedom to provide highly individualized, exceptional care to each patient. MSK is consistently ranked the number-one hospital for cancer care in the Northeast and among the top two cancer hospitals nationwide. And its always-evolving educational programs continue to train new leaders in the field, here and around the world. For more information, visit www.mskcc.org.

The Rockefeller University
The Rockefeller University is one of the world’s leading biomedical research universities and is dedicated to conducting innovative, high-quality research to improve the understanding of life for the benefit of humanity. Its 82 laboratories conduct research in neuroscience, immunology, biochemistry, genomics and many other areas, and a community of over 2,000 faculty, students, postdocs, technicians, clinicians and administrative personnel work on a 14-acre Manhattan campus. Rockefeller’s unique approach to science has led to some of the world’s most revolutionary and transformative contributions to biology and medicine. During Rockefeller’s 115-year history, 25 of its scientists have won Nobel Prizes, 22 have won Albert Lasker Medical Research Awards and 20 have garnered the National Medal of Science, the highest science award given by the United States.

Weill Cornell Medicine
Weill Cornell Medicine is committed to excellence in patient care, scientific discovery and the education of future physicians in New York City and around the world. The doctors and scientists of Weill Cornell Medicine — faculty from Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, and Weill Cornell Physician Organization — are engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies. Located in the heart of the Upper East Side’s scientific corridor, Weill Cornell Medicine’s powerful network of collaborators extends to its parent university Cornell University; to Qatar, where Weill Cornell Medicine–Qatar offers a Cornell University medical degree; and to programs in Tanzania, Haiti, Brazil, Austria and Turkey. Weill Cornell Medicine faculty provide comprehensive patient care at NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian Lower Manhattan Hospital, NewYork-Presbyterian Queens and NewYork-Presbyterian Brooklyn Methodist Hospital. Weill Cornell Medicine is also affiliated with Houston Methodist. For more information, visit weill.cornell.edu.

Takeda Pharmaceutical Company, Ltd.
Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries. For more information, visit www.takeda.com/newsroom.